Invesco
PRME icon

Invesco’s Prime Medicine PRME Stock Holding History

Invesco’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Buy
140,308
+43,433
+45% +$144K ﹤0.01% 3221
2026
Q1 		$337K Buy
96,875
+40,096
+71% +$153K ﹤0.01% 3298
2025
Q4 		$197K Sell
56,779
-705,299
-93% -$3.14M ﹤0.01% 3533
2025
Q3 		$4.22M Buy
762,078
+748,416
+5,478% +$3.04M ﹤0.01% 2308
2025
Q2 		$33.7K Sell
13,662
-1,174
-8% -$1.81K ﹤0.01% 3743
2025
Q1 		$29.5K Sell
14,836
-235
-2% -$599 ﹤0.01% 3729
2024
Q4 		$44K Buy
15,071
+1,048
+7% +$3.68K ﹤0.01% 3703
2024
Q3 		$54.3K Buy
14,023
+586
+4% +$2.71K ﹤0.01% 3676
2024
Q2 		$69.1K Buy
13,437
+2,826
+27% +$17.1K ﹤0.01% 3790
2024
Q1 		$74.3K Buy
+10,611
New +$80.5K ﹤0.01% 3768

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Invesco's PRME Position: Q2 2026 in Review

Invesco increased its Prime Medicine (PRME) stake by 45% in Q2 2026, buying an estimated $144K and bringing the position to 140,308 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

Invesco first reported a position in PRME in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.22M in Q3 2025. 188 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Invesco held 140,308 shares of Prime Medicine worth $518K as of Q2 2026.
  • Invesco bought 43,433 Prime Medicine shares in Q2 2026, an estimated $144K.
  • Prime Medicine made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3221 holding.
  • Invesco first reported a position in Prime Medicine in Q1 2024 and has held it in 10 quarters since.
  • Invesco's Prime Medicine position peaked at $4.22M in Q3 2025.
  • 188 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.